<DOC>
	<DOCNO>NCT00053248</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Imatinib mesylate may stop growth cancer cell block enzymes necessary cancer cell growth . Combining chemotherapy imatinib mesylate may kill cancer cell . PURPOSE : Phase I/II trial study effectiveness combine arsenic trioxide imatinib mesylate treat patient chronic phase chronic myelogenous leukemia .</brief_summary>
	<brief_title>Arsenic Trioxide Imatinib Mesylate Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety tolerability arsenic trioxide imatinib mesylate patient resistant chronic phase chronic myelogenous leukemia . - Determine potential dose-limiting toxic effect patient treat regimen . - Determine pharmacokinetics regimen patient . OUTLINE : This multicenter study . Patients receive oral imatinib mesylate daily arsenic trioxide IV 1-2 hour day 1-5 week 1 twice weekly . Treatment continue 1 year absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 18-24 patient ( least 6 patient phase I least 12 patient phase II ) accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytogenetically confirm Philadelphia chromosomepositive ( Ph+ ) chronic myelogenous leukemia , meet one follow criterion : Chronic phase Less 15 % blast peripheral blood marrow Less 30 % blast promyelocytes peripheral blood marrow Less 20 % basophil blood marrow Platelet count least 100,000/mm^3 ( unless therapy relate ) No progressive ( increase least 10 cm 4 past 24 week ) exist ( great 10 cm ) splenomegaly Complete hematologic response ( CHR ) No immature myeloid cell peripheral blood No increase basophils peripheral blood WBC le upper limit normal ( ULN ) Platelet count less ULN No major ( less 35 % Ph+ ) complete ( 0 % Ph+ ) cytogenetic response least 6 month imatinib mesylate Loss prior major cytogenetic response failure achieve major cytogenetic response PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Bilirubin less 1.5 time ULN AST ALT less 2.5 time ULN Renal Creatinine less 1.5 time ULN Cardiovascular No New York Heart Association grade III IV congestive heart failure No untreated symptomatic cardiac ischemia No underlying cardiac arrhythmia , include limited following : Conduction abnormality/atrioventricular heart block Nodal/junctional arrhythmia/dysrhythmia Sinus bradycardia tachycardia Supraventricular tachycardia Ventricular arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use 2 method effective barrier contraception 3 month study Electrolyte level ( especially potassium magnesium ) normal ( CHR patient ) No history noncompliance would preclude study participation No concurrent serious , uncontrolled medical condition No grade 2 great neuropathy PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other More 14 day since prior therapy except hydroxyurea , anagrelide hydrochloride , imatinib mesylate More 28 day since prior investigational agent No concurrent grapefruit grapefruit juice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
</DOC>